Study of Efficacy and Safety of Brodalumab Compared With Placebo in Inadequately Controlled Asthma Subjects With High Bronchodilator Reversibility

Inclusion Criteria:

- Diagnosis of asthma, and presently has reversibility over pre-bronchodilator FEV1 of
≥ 20% at screening

- Percent of predicted FEV1 ≥ 40% and ≤ 80% at screening

- ICS ≥ 200 and ≤ 1000/μg/day fluticasone powder or equivalent

- Ongoing asthma symptoms with ACQ composite score at screening and baseline ≥ 1.5
points

Exclusion Criteria:

- History of chronic obstructive pulmonary disease or other chronic pulmonary condition
other than asthma

- History of allergic bronchopulmonary aspergillosis

- Respiratory infection within 4 weeks of screening or 1 week of baseline visit

- Subject has known history of Crohn's disease Subject has any other significant
concurrent medical condition of laboratory abnormalities, as defined in the study
protocol

- Subject has previously used any anti-IL17 biologic therapy

- Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled
in the study

- Female subject is unwilling to use highly effective methods of birth control unless 2
years post-menopausal or surgically sterile

- Subject has severe depression measured by Personal Health Questionnaire Depression
Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide
Severity Rating Scale (e-CSSRS)

- Subject has a history or evidence of psychiatric disorder or substance abuse
considered by the Investigator to pose a risk to subject safety